• Je něco špatně v tomto záznamu ?

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

L. de Swart, S. Crouch, M. Hoeks, A. Smith, S. Langemeijer, P. Fenaux, A. Symeonidis, J. Cermâk, E. Hellström-Lindberg, R. Stauder, G. Sanz, M. Mittelman, MS. Holm, L. Malcovati, K. Mądry, U. Germing, A. Tatic, A. Savic, AM. Almeida, N....

. 2020 ; 105 (3) : 632-639. [pub] 20190606

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020714

Progression-free survival (PFS) of patients with lower-risk myelodysplastic syndromes (MDS) treated with red blood cell transfusions is usually reduced, but it is unclear whether transfusion dose density is an independent prognostic factor. The European MDS Registry collects prospective data at 6-monthly intervals from newly diagnosed lower-risk myelodysplastic syndromes patients in 16 European countries and Israel. Data on the transfusion dose density - the cumulative dose received at the end of each interval divided by the time since the beginning of the interval in which the first transfusion was received - were analyzed using proportional hazards regression with time-varying co-variates, with death and progression to higher-risk MDS/acute myeloid leukemia as events. Of the 1,267 patients included in the analyses, 317 died without progression; in 162 patients the disease had progressed. PFS was significantly associated with age, EQ-5D index, baseline World Health Organization classification, bone marrow blast count, cytogenetic risk category, number of cytopenias, and country. Transfusion dose density was inversely associated with PFS (P<1×10-4): dose density had an increasing effect on hazard until a dose density of 3 units/16 weeks. The transfusion dose density effect continued to increase beyond 8 units/16 weeks after correction for the impact of treatment with erythropoiesis-stimulating agents, lenalidomide and/or iron chelators. In conclusion, the negative effect of transfusion treatment on PFS already occurs at transfusion densities below 3 units/16 weeks. This indicates that transfusion dependency, even at relatively low dose densities, may be considered as an indicator of inferior PFS. This trial was registered at www.clinicaltrials.gov as #NCT00600860.

Center for Clinical Transfusion Research Sanquin Research Leiden the Netherlands

Center of Hematology and Bone Marrow Transplantation Fundeni Clinical Institute Bucharest Romania

Clinic of Hematology Clinical Center of Vojvodina Faculty of Medicine University of Novi Sad Novi Sad Serbia

Department of Clinical Hematology Hospital da Luz Lisbon Portugal

Department of Clinical Hematology Institute of Hematology and Blood Transfusion Praha Czech Republic

Department of Haematology Aberdeen Royal Infirmary Aberdeen UK

Department of Hematology Aarhus University Hospital Aarhus Denmark

Department of Hematology Democritus University of Thrace Medical School University Hospital of Alexandroupolis Alexandroupolis Greece

Department of Hematology Hospital Universitario y Politécnico La Fe Valencia Spain

Department of Hematology Oncology and Clinical Immunology Universitatsklinik Düsseldorf Düsseldorf Germany

Department of Hematology Oncology and Internal Medicine Warsaw Medical University Warsaw Poland

Department of Hematology Oncology Fondazione IRCCS Policlinico San Matteo University of Pavia Pavia Italy

Department of Hematology Radboud University Medical Center Nijmegen the Netherlands

Department of Internal Medicine 5 Innsbruck Medical University Innsbruck Austria

Department of Internal Medicine Division of Hematology Merkur University Hospital Zagreb Croatia

Department of Medicine A Tel Aviv Sourasky Medical Center and Sackler Medical Faculty Tel Aviv University Tel Aviv Israel

Department of Medicine Division of Hematology Karolinska Institutet Stockholm Sweden

Department of Medicine Division of Hematology University of Patras Medical School Patras Greece

Department of Tumor Immunology Nijmegen Center for Molecular Life Sciences Radboud University Medical Center Nijmegen the Netherlands

Epidemiology and Cancer Statistics Group Department of Health Sciences University of York York UK

Service d'Hématologie Centre Hospitalier Universitaire Brabois Vandoeuvre Nancy France

Service d'Hématologie Hôpital Saint Louis Assistance Publique des Hôpitaux de Paris and Université Paris 7 Paris France

Service de Médecine Interne IUCT Oncopole CHU Toulouse Toulouse France

St James's Institute of Oncology Leeds Teaching Hospitals Leeds UK

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020714
003      
CZ-PrNML
005      
20210830102332.0
007      
ta
008      
210728s2020 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2018.212217 $2 doi
035    __
$a (PubMed)31171638
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a de Swart, Louise $u Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands
245    10
$a Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes / $c L. de Swart, S. Crouch, M. Hoeks, A. Smith, S. Langemeijer, P. Fenaux, A. Symeonidis, J. Cermâk, E. Hellström-Lindberg, R. Stauder, G. Sanz, M. Mittelman, MS. Holm, L. Malcovati, K. Mądry, U. Germing, A. Tatic, A. Savic, AM. Almeida, N. Gredelj-Simec, A. Guerci-Bresler, O. Beyne-Rauzy, D. Culligan, I. Kotsianidis, R. Itzykson, C. van Marrewijk, N. Blijlevens, D. Bowen, T. de Witte, EUMDS Registry Participants
520    9_
$a Progression-free survival (PFS) of patients with lower-risk myelodysplastic syndromes (MDS) treated with red blood cell transfusions is usually reduced, but it is unclear whether transfusion dose density is an independent prognostic factor. The European MDS Registry collects prospective data at 6-monthly intervals from newly diagnosed lower-risk myelodysplastic syndromes patients in 16 European countries and Israel. Data on the transfusion dose density - the cumulative dose received at the end of each interval divided by the time since the beginning of the interval in which the first transfusion was received - were analyzed using proportional hazards regression with time-varying co-variates, with death and progression to higher-risk MDS/acute myeloid leukemia as events. Of the 1,267 patients included in the analyses, 317 died without progression; in 162 patients the disease had progressed. PFS was significantly associated with age, EQ-5D index, baseline World Health Organization classification, bone marrow blast count, cytogenetic risk category, number of cytopenias, and country. Transfusion dose density was inversely associated with PFS (P<1×10-4): dose density had an increasing effect on hazard until a dose density of 3 units/16 weeks. The transfusion dose density effect continued to increase beyond 8 units/16 weeks after correction for the impact of treatment with erythropoiesis-stimulating agents, lenalidomide and/or iron chelators. In conclusion, the negative effect of transfusion treatment on PFS already occurs at transfusion densities below 3 units/16 weeks. This indicates that transfusion dependency, even at relatively low dose densities, may be considered as an indicator of inferior PFS. This trial was registered at www.clinicaltrials.gov as #NCT00600860.
650    _2
$a transfuze erytrocytů $x škodlivé účinky $7 D017707
650    _2
$a lidé $7 D006801
650    12
$a myelodysplastické syndromy $x terapie $7 D009190
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a prospektivní studie $7 D011446
651    _2
$a Evropa $7 D005060
651    _2
$a Izrael $x epidemiologie $7 D007557
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Crouch, Simon $u Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK
700    1_
$a Hoeks, Marlijn $u Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands $u Center for Clinical Transfusion Research, Sanquin Research, Leiden, the Netherlands
700    1_
$a Smith, Alex $u Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK
700    1_
$a Langemeijer, Saskia $u Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands
700    1_
$a Fenaux, Pierre $u Service d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris and Université Paris 7, Paris, France
700    1_
$a Symeonidis, Argiris $u Department of Medicine, Division of Hematology, University of Patras Medical School, Patras, Greece
700    1_
$a Cermâk, Jaroslav $u Department of Clinical Hematology, Institute of Hematology & Blood Transfusion, Praha, Czech Republic
700    1_
$a Hellström-Lindberg, Eva $u Department of Medicine, Division of Hematology, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Stauder, Reinhard $u Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria
700    1_
$a Sanz, Guillermo $u Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain
700    1_
$a Mittelman, Moshe $u Department of Medicine A, Tel Aviv Sourasky (Ichilov) Medical Center and Sackler Medical Faculty, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Holm, Mette Skov $u Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
700    1_
$a Malcovati, Luca $u Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
700    1_
$a Mądry, Krzysztof $u Department of Hematology, Oncology and Internal Medicine, Warsaw Medical University, Warsaw, Poland
700    1_
$a Germing, Ulrich $u Department of Hematology, Oncology and Clinical Immunology, Universitatsklinik Düsseldorf, Düsseldorf, Germany
700    1_
$a Tatic, Aurelia $u Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania
700    1_
$a Savic, Aleksandar $u Clinic of Hematology - Clinical Center of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
700    1_
$a Almeida, Antonio Medina $u Department of Clinical Hematology, Hospital da Luz, Lisbon, Portugal
700    1_
$a Gredelj-Simec, Njetocka $u Department of Internal Medicine, Division of Hematology, Merkur University Hospital, Zagreb, Croatia
700    1_
$a Guerci-Bresler, Agnes $u Service d'Hématologie, Centre Hospitalier Universitaire (CHU) Brabois Vandoeuvre, Nancy, France
700    1_
$a Beyne-Rauzy, Odile $u Service de Médecine Interne, IUCT-Oncopole, CHU Toulouse, Toulouse, France
700    1_
$a Culligan, Dominic $u Department of Haematology, Aberdeen Royal Infirmary, Aberdeen, UK
700    1_
$a Kotsianidis, Ioannis $u Department of Hematology, Democritus University of Thrace Medical School, University Hospital of Alexandroupolis, Alexandroupolis, Greece
700    1_
$a Itzykson, Raphael $u Service d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris and Université Paris 7, Paris, France
700    1_
$a van Marrewijk, Corine $u Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands
700    1_
$a Blijlevens, Nicole $u Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands
700    1_
$a Bowen, David $u St. James's Institute of Oncology, Leeds Teaching Hospitals, Leeds, UK
700    1_
$a de Witte, Theo $u Department of Tumor Immunology - Nijmegen Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands theo.dewitte@radboudumc.nl
710    2_
$a EUMDS Registry Participants
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 105, č. 3 (2020), s. 632-639
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31171638 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102332 $b ABA008
999    __
$a ok $b bmc $g 1691319 $s 1141160
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 105 $c 3 $d 632-639 $e 20190606 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace